Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern

4 Oct 2024

Abstract excerpt

The emergence of new SARS-CoV-2 variants of concern associated with waning immunity induced by natural infection or vaccines currently in use suggests that the COVID-19 pandemic will become endemic. Investing in new booster vaccines using different platforms is a promising way to enhance protection and keep the disease under control. Here, we evaluated the immunogenicity, efficacy, and safety of the SpiN-Tec...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39368129
DOI: 10.1016/j.vaccine.2024.126394

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concernPMID 39368129Read ↗

Translational Virology - COVID-19, The Perfect ExampleSemantic proximity Read ↗

A conserved region T-cell vaccine for SarbecovirusesSemantic proximity Read ↗

Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human PrimatesSemantic proximity Read ↗

OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge modelSemantic proximity Read ↗

Immunization with Recombinant Accessory Protein-Deficient SARS-CoV-2 Protects against Lethal Challenge and Viral TransmissionSemantic proximity Read ↗

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infectionSemantic proximity Read ↗

An Overview of Vaccine Development for COVID-19Semantic proximity Read ↗

Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum ProtectionSemantic proximity Read ↗

Immunization With a RBD/Nucleocapsid Fusion Protein Promotes Neutralizing Antibody-Independent Resistance to the Wild-Type and the Delta Variant of SARS-CoV-2Semantic proximity Read ↗

Essential Considerations During Vaccine Design against COVID-19 and Review of Pioneering Vaccine Candidate PlatformsSemantic proximity Read ↗

UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of ConcernSemantic proximity Read ↗

Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.